Low oxygen and nutrient depletion play critical roles in tumorigenesis, but little is known about how they interact to produce tumor survival and tumor malignancy. In the present study, we investigated the mechanism underlying hypoxia-modulated apoptosis of serum-deprived HepG2 cells. Our results showed that hypoxia blocked the apoptosis, which was accompanied with decreased Bax/ Bcl-2 ratio, inhibited cytochrome c release, and reduced caspase-3 activity. More importantly, increased expressions of VEGF and its receptor-2 (KDR) under hypoxic/ serum-deprived condition suggest that VEGF may act as a survival factor in a self-promoting manner. Data were further supported by results that recombinant human VEGF (rhVEGF) suppressed the serum deprivationinduced apoptosis, and anti-VEGF neutralizing antibody block anti-apoptotic activity of hypoxia. In addition, inhibitors of receptor tyrosine kinase blocked antiapoptosis of hypoxia. Our study further showed that rhVEGF or hypoxia induced ERK phosphorylation in serum-deprived cells, and that a speci®c inhibitor of MAPK/ERK, PD98059 eliminated the anti-apoptotic activity of rhVEGF or hypoxia by increasing Bax/Bcl-2 ratio and caspase-3 activity. Our data led us to conclude that induction of ERK phosphorylation and decrease of Bax/Bcl-2 ratio by rhVEGF implies that hypoxiainduced VEGF prevents apoptosis of serum-deprived cells by activating the MAPK/ERK pathway. Taken together, we propose that hypoxia enhances survival of nutrient-depleted tumor cells by reducing susceptibility to apoptosis, which consequently leads to tumor malignancy. Oncogene (2000) 19, 4621 ± 4631.
Introduction
The stereotypical features of a cell undergoing apoptosis include phosphatidylserine externalization, DNA fragmentation, nuclear condensation, cell shrinkage, and blebbing (Wyllie et al., 1980) . These events are mediated by the activation of several caspases, which then induce apoptosis via cleavage of key substrates (Henkart, 1996; Chinnaiyan and Dixit, 1996) . Early in apoptotic process, mitochondria releases cytochrome c that enters cytosol and forms a complex with Apaf-1 and a pro-form of caspase-9 (Liu et al., 1996) . These complexes activate other caspases, in particular caspase-3, -6 and -7 (Li et al., 1997) . In addition, a pro-apoptotic protein, Bax induces cytochrome c release and caspase activation, resulting in apoptosis, which are blocked by anti-apoptotic proteins, Bcl-2 and Bcl-xL (Finucane et al., 1999) .
Hypoxic and low-nutrient environments are commonly found in the central region of solid tumors (Harrington et al., 1994; Dang and Semenza, 1999) . These microenvironments cause a wide range of responses at both systemic and cellular levels including gene expressions, angiogenesis, changes of metabolic switch, and apoptosis (Semenza et al., 1994; Hockel et al., 1996; Bae et al., 1998) . Since solid tumors endure hypoxia before the formation of microvessels, adaptive responses to hypoxia and insucient nutrients are crucial steps in tumor progression (Towle, 1995) . Among these responses, hypoxia causes a metabolic shift from oxidative metabolism to glycolysis, as evidenced by increased expressions of glycolytic enzymes and glucose transporters (Rempel et al., 1996; Younes et al., 1996) . Therefore, tumor cells are more ecient in energy metabolism through increased glycolysis and glucose transport.
However, little is known about how tumors can surmount growth factor depletion and manage to proliferate. Shortage of growth factor in tumor cells exhibits various biological responses, including growth arrest, inhibition of protein synthesis, and induction of apoptosis (Satoh et al., 1996; Boix et al., 1998) . Recent reports show that anti-apoptotic agents prevent apoptosis by blocking the activation of apoptosisinducing factors (Gotz et al., 1999) . For example, VEGF protects endothelial cells from serum deprivation-or ceramide-induced apoptosis, and activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway is involved in the anti-apoptotic process (Mukhopadhyay et al., 1998; Gupta et al., 1999) . These reports strongly imply that factors involved in tumorigenesis can modulate apoptosis independently.
On the basis of ®ndings that microenvironments play important roles during tumor development, much interest has been focused on how transformed cells respond to tumor environment (Ausserer et al., 1994; Rupec and Baeuerle, 1995) . In the present study, we conducted a series of studies to determine which factors can manipulate tumor survival and proliferation, using HepG2 cells incubated under hypoxic and/ or serum-deprived conditions. We focused on VEGF because of its key role as a major angiogenic factor in most solid tumors. Our results clearly showed that hypoxia inhibits apoptosis of serum-deprived HepG2 cells via increasing VEGF, activation of MAPK/ERK signaling pathway and subsequent decrease of Bax/Bcl-2 ratio.
Results

Effect of hypoxic treatment on apoptosis of serum-deprived HepG2 cells
To investigate the eect of hypoxia on serum deprivation-induced apoptosis, we imposed hypoxia on serum-deprived HepG2 cells. As shown in Figure  1a , DNA fragmentation was induced in HepG2 cells grown under serum-deprived media (0% FBS) compared to control cells under normal growth media (10% FBS) (lane 2). Interestingly, however, hypoxia signi®cantly reduced the DNA fragmentation ( Figure 1a , lane 3). This anti-apoptotic eect of hypoxia on serum-deprived cells was also shown in the quantitative analysis of fragmented DNA using (Figure 1b) . When nuclear morphology was assessed by DAPI staining, control cells exhibited normal distribution of chromosomal DNA, whereas serum-deprived cells showed condensed chromatins and fragmented nuclei ( Figure  1c ). In contrast, hypoxia dramatically reduced cell population exhibiting chromatin condensation and nucleus fragmentation under serum-deprived condition (Figure 1c) .
To investigate the early stage of apoptosis, the number of annexin V-positive cells that indicate phosphatidylserine externalization of apoptotic cells were counted using FACScan¯ow cytometry. Annexin V-positive cells were increased by serum deprivation for 12 h, but decreased by the introduction of hypoxia to serum-deprived cells (Figure 2a) . These results were also con®rmed by the quantitation of apoptotic subdiploid cells. As shown in Figure 2b , the percentage of sub-diploid cells was increased to 32.5% by serum deprivation, but decreased to 15.3% by hypoxia in serum-deprived cells. These results suggest that hypoxia suppresses apoptosis of serum-deprived cells in the early as well as late stages. Figure 1 Eect of hypoxia on serum deprivation-induced apoptosis. (a) HepG2 cells were treated with hypoxia and/or serum deprivation for 36 h. DNA were isolated and electrophoresed on 1.5% agarose gel, and then photographed after ethidium bromide staining. 10 mM cycloheximide (CHX) was pretreated for 2 h and then incubated for 36 h under hypoxia and/or serum-deprived conditions (lanes 4, 5, and 6). M, 1 kb marker. (b) The fragmented DNA was quantitated using [ Recent reports show that Bcl-2 family is a major regulator of apoptosis, and Bax/Bcl-2 ratio appears to be an important determinant in the regulation of apoptosis (Wyllie, 1995; Finucane et al., 1999) . To test the involvement of Bcl-2 family, we investigated their expression under hypoxic and/or serum-deprived conditions. Bax was signi®cantly increased in serum-deprived HepG2 cells with a concomitant decrease of Bcl-2, whereas expression of Bcl-xL did not show signi®cant changes (Figure 3a,b) . Furthermore, Bax/Bcl-2 ratio was increased to 4.5-fold under normoxic/serum-deprived To measure DNA contents of individual cells incubated for 36 h under hypoxic and/or serum-deprived conditions, cells were stained with PI, and the number of sub-diploid cells were countered using FACScan¯ow cytometry. Cells with a subdiploid DNA content (45% of G 0 content) were considered to be apoptotic. The distribution of cell cycle was analysed with ModiFitLT V2.0. Data represents mean values of three replicates, with bars indicating s.e.m. *P50.05 compared to control and #P50.05 compared to serum deprivation alone condition, but reduced to almost the same level of the control under hypoxic/serum-deprived condition ( Figure  3c ). These results strongly indicate that hypoxia decreased the serum deprivation-induced apoptosis by modulating Bax/Bcl-2 balance.
Cytochrome c release and caspase-3 activation Activation of caspases is regulated by cytochrome c release from mitochondria to cytosol (Kluck et al., 1997; Kroemer et al., 1998) . The present study also showed that cytochrome c release was markedly induced by serum deprivation, while hypoxia signi®-cantly reduced the release (Figure 4a ). We con®rmed these results by caspase-3 activity assay. As shown in Figure 4b , caspase-3 activity was increased threefold by serum deprivation, but hypoxia decreased to 1.5-fold compared to control cells. These results suggest that hypoxia blocks apoptosis through inhibiting cytochrome c release and caspase-3 activation in serumdeprived cells.
Effect of VEGF and its receptors on the apoptosis of serum-deprived cells
VEGF synthesized by tumor cells accumulates in nearby blood vessels where it acts as an angiogenic and mitogenic factor (Dvorak et al., 1991) . In addition to be a potent endothelial mitogen, VEGF acts as an endothelial cell survival factor in vivo (Alon et al., 1995; Holash et al., 1999) . In the present study, we determined whether growth factors synthesized in solid tumors, such as VEGF, IGF-II, bFGF and EGF, can aect survival of serum-deprived HepG2 cells. Among the growth factors tested, rhVEGF was the most eective factor on tumor cell survival under serum-deprived condition ( Figure 5a ). Hypoxia enhanced substantially the synthesis of VEGF mRNA and the protein (Figure 5b ,c) in serum-deprived cells. To con®rm the eect of hypoxia-induced VEGF, anti-rhVEGF neutralizing antibody was treated on serum-deprived cells under hypoxia. As shown in Figure  5d , anti-VEGF neutralizing antibody signi®cantly increased DNA fragmentation in serum-deprived cells under hypoxia. The results of caspase-3 activity assay were consistent with that of DNA fragmentation assay ( Figure 5e ). These results suggest that hypoxia-induced VEGF is responsible factor for survival of serumdeprived HepG2.
To identify the signaling pathway of hypoxiainduced VEGF on HepG2 cell survival, we investigated the expression of VEGF receptors and the eect of inhibitors that were known as blockers of receptor tyrosine kinase (Takahashi et al., 1999; Piossek et al., 1999) . As shown in Figure 6a , VEGF receptor-2 (KDR) was signi®cantly increased in hypoxic/serumdeprived cells. Staurosporine, genistein and tyrphostin-47, inhibitors of receptor tyrosine kinase (RTK) signi®cantly enhanced the DNA fragmentation and caspase-3 activation that were reduced by hypoxia in Figure 3 Eect of hypoxia on bax and bcl-2 expressions. HepG2 cells were exposed to hypoxia and/or serum deprivation for 24 h. (a) Total protein was isolated for immunoblot analysis using speci®c antibodies. (b) cDNA was prepared from total RNA and served as a template for PCR. PCR products were elecrophoresed, blotted onto nylon membrane, and hybridized with a-32 Plabeled bax or bcl-2 cDNA fragment for Southern blot analysis. b-actin was used for an internal control. (c) The band intensity was analysed using an image analysis software, TINA2.0, and data represents the induction fold of Bax/Bcl-2 ratio after normalization with a-tubulin band Figure 4 Inhibition of cytochrome c release and caspase-3 activation by hypoxia. HepG2 cells were treated with hypoxia and/or serum deprivation for 36 h, and (a) cytosolic protein was isolated to detect cytochrome c release. (b) Caspase-3 activity was measured by reading samples in¯uorescence microplate reader. Data represents relative activity of caspase-3 after normalization with protein amounts. Data indicate mean values of three replicates, with bars indicating s.e.m. *P50.05 compared to control and #P50.05 compared to serum deprivation alone Figure 5 Expression of VEGF and anti-apoptotic eect of rhVEGF. (a) Cells were treated with serum deprivation for 36 h with or without rhVEGF (100 ng/ml), EGF (100 ng/ml), bFGF (20 ng/ml), or IGF-II (100 ng/ml), and DNA fragmentation analysis was performed. (b) After exposure to hypoxic and/or serum-deprived conditions for indicated time was prepared, and Northern blot analysis was performed with a-32 P-labeled VEGF cDNA fragment. (c) After incubation for 24 h, total protein was isolated, and used for immunoblot analysis using speci®c antibodies. (d) DNA fragmentation assay and (e) caspase-3 activity assay were performed with the cells treated by hypoxia and/or serum deprivation with or without rhVEGF (100 ng/ml) or anti-VEGF neutralizing monoclonal antibody (10 mg/ml) for 36 h. Data represents relative activity of caspase-3 after normalization with protein amounts. Data indicate mean values of three replicates, with bars indicating s.e.m. *P50.05 compared to control, #P50.05 compared to serum deprivation alone, and + x P50.05 compared to hypoxia/serum deprivation serum-deprived cells (Figure 6b,c) . These results suggest that hypoxia-induced VEGF induces antiapoptosis of serum-deprived HepG2 cells through its receptor-2, KDR signaling pathway.
Effects of rhVEGF and hypoxia on MAPK/ERK pathway in serum-deprived HepG2 cells
As reported recently, a member of the MAP kinase superfamily, ERK 1 and 2 have also been reported to be involved in VEGF-induced anti-apoptosis in serumdeprived endothelial cells (Gupta et al., 1999) . To discern the involvement of MAPK/ERK pathway in anti-apoptosis of hypoxia and rhVEGF, we used a speci®c inhibitor of MAPK/ERK, PD98059 on serumdeprived HepG2 cells. As shown in Figure 7a , PD98059 resulted in marked DNA fragmentation in hypoxic/ serum-deprived cells (lanes 4 and 8) and completely blocked the anti-apoptotic eect of rhVEGF (lanes 9 and 10). However, rhVEGF signi®cantly reduced the apoptosis of serum-deprived cells in a dose-dependent manner (Figure 7a, lanes 6 and 7) . PD98059 also increased the apoptotic sub-diploid cells previously decreased by rhVEGF in serum-deprived cells ( Figure  7b ). In addition, caspase-3 activity was increased by treatment of PD98059 under hypoxic/serum-deprived condition, suggesting the involvement of ERK in hypoxia-induced anti-apoptosis (Figure 7c ). The result that rhVEGF or hypoxia increased phosphorylation of MAPK/ERK (Figure 7d , upper panel) without aecting the total amount of MAPK/ERK (lower panel) supports the notion on hypoxia-induced VEGF that may mediate anti-apoptosis via activation of PD98059-sensitive protein kinase, MAPK/ERK.
Regulation of bax, bcl-2 and VEGF expression by hypoxia and rhVEGF
From our results, it is expected that Bax and Bcl-2 are important factors in the rhVEGF-induced anti-apoptosis, because of their role as major regulators of apoptosis in several tumor cells (Finucane et al., 1999) . To test the possibility, we performed RT ± PCR and immunoblot analysis for detection of bax and bcl-2 expressions. As shown in Figure 8 , in contrast to the decreased bax, bcl-2 expression was signi®cantly induced by addition of rhVEGF in serum-deprived cells (Figure 8a , lane 5) compared to serum-deprivation alone. This result was also con®rmed with their protein levels ( Figure 8b, lane 5) . Interestingly, co-treatment of PD98059 with rhVEGF reversed changes in the expressions of bax and bcl-2 in serum-deprived cells to similar levels as that of serum deprivation alone (Figure 8a,b, lanes 2 and 6) . Similarly, treatment of PD98059 in hypoxic/serum-deprived cells strongly induced the bax expression while suppressing the bcl-2 expression (Figure 8a,b, lane 4) . This dierential expression of bax and bcl-2 may play an important role in regulation of anti-apoptotic activity of hypoxia or rhVEGF. The signi®cantly decreased Bax/Bcl-2 ratio by rhVEGF and hypoxia, and its reversal by PD98059 to similar levels as that of serum deprivation ( Figure  8c , upper panel) suggest that MAPK/ERK is likely engaged in the VEGF-induced down-regulation of bax and up-regulation of bcl-2 in serum-deprived cells.
Although rhVEGF slightly increased the expression of VEGF in serum-deprived HepG2 cells, hypoxiainduced VEGF expression was not aected by PD98059 in hypoxic/serum-deprived cells (Figure 8 ). These results imply that hypoxia induces the expression of VEGF followed by activation of the MAPK/ERK signaling pathway. This signaling pathway may direct the expressions of bax and bcl-2, resulting in suppressing of apoptosis.
Discussion
The solid tumors in early stages possess poorly developed blood vessels, leading to the deprivations Figure 6 Expression of VEGF receptor and the involvement of its signaling pathway. (a) After exposure to hypoxic and/or serum-deprived conditions for 24 h, total protein was prepared and used for immunoblot analysis with anti-KDR polyclonal antibody. Tyrphostin-47 (40 mM), staurosporine (200 nM) and genistein (100 mM) were exposed serum-deprived cells under hypoxia for 36 h. (b) Total DNA was used for DNA fragmentation assay, and (c) protein was used for caspase-3 activity assay. Data indicate mean values of three replicates, with bars indicating s.e.m. *P50.05 compared to control, #P50.05 compared to serum deprivation alone, and + x P50.05 compared to hypoxia/serum deprivation of both oxygen and nutrients in the central region (Symonds et al., 1994) . These conditions often induce apoptosis, but also elicit tumor malignancy through genetic alterations, such as loss of p53 gene or overexpression of anti-apoptotic protein, Bcl-2 and Bcl-xL, which may causes decreased susceptibility to apoptosis (Graeber et al., 1996) . However, data from the present study reveal an alternative mechanism for surmounting apoptosis in solid tumors: hypoxia in solid tumors stimulates the VEGF expression, which may act as a survival and mitogenic factor, resulting in antiapoptosis and proliferation of tumor cells.
Recent reports show that most tumor cells can not only survive under serum-deprived condition, but manage solid tumors to form tumor mass (Boix et al., 1998) . Hypoxia in solid tumor causes a metabolic switch from oxidative metabolism to glycolysis via increased glycolytic enzymes and glucose transporters, Figure 7 Involvement of the MAPK/ERK pathway in anti-apoptosis of rhVEGF or hypoxia. After treatment of hypoxia and/or rhVEGF (50 or 100 ng/ml) with or without 50 mM PD98059 for 36 h, (a) total DNA was used for DNA fragmentation assay, and (b) the number of subdiploid cells was countered using FACScan¯ow cytometry. (c) Caspase-3 activity assay was performed using total protein. Data indicate mean values of three replicates, with bars indicating s.e.m. *P50.05 compared to control, #P50.05 compared to serum deprivation alone, and + x P50.05 compared to serum deprivation with rhVEGF or hypoxia/serum deprivation. (d) Transient activation of MAPK/ERK by rhVEGF (100 ng/ml) or hypoxia in serum-deprived HepG2 cells was assessed by immunoblot analysis with anti-phospho-ERK monoclonal antibody and anti-ERK polyclonal antibody as tumors display a high rate of glycolysis and an increase of glucose transport (Dang and Semenza, 1999) . However, how these tumor cells can survive without getting growth factors from blood has not been answered satisfactorily. Indications are that some viable mechanisms prevail for the situation with a limited growth factor supply in vivo. In this regards, it is important to realize that hypoxia increases the expressions of several growth factors, including EGF, IGF-II, bFGF, and VEGF (Levy et al., 1995; . Therefore, one might expect that hypoxia contributes to cell survival of serum-deprived cells. Our present data clearly showed that hypoxia suppressed apoptosis of serum-deprived HepG2 cells (Figures 1  and 2 ). Moreover, our data showed that the suppression was modulation of Bax/Bcl-2 ratio with a suppression of cytochrome c release and caspase-3 activation (Figures 3 and 4) . These results are taken together as strong evidence that hypoxia under serumdeprived condition suppresses proapoptotic genes, making tumor cells less susceptible to apoptosisinducing stimuli.
Many reports demonstrate that tumor cells undergo adaptive processes, such as growth inhibition, genetic alterations, and angiogenesis in response to hypoxia or serum deprivation (Levy et al., 1995; Graeber et al., 1996) . Notably, hypoxia induces transcriptional activation of erythropoietin (EPO), VEGF, and glycolytic enzymes (Schuster et al., 1989; Kim et al., 1998) . These responses, likely enhance oxygen delivery and ATP production by glycolytic pathway (Rempel et al., 1996; Dang and Semenza 1999) . It was also reported that rhVEGF prevents serum deprivation-induced apoptosis of human microvascular endothelial cells via activation of the MAPK/ERK signaling pathway (Kroll and Waltenberger, 1997; Gupta et al., 1999) . Based on these reports, we expected that hypoxia-induced growth factors might exert a protective eect on the apoptosis in solid tumors. Indeed in the present study, we examined the eects of tumor-derived growth factors, including IGF-II, bFGF, EGF and VEGF, on serum deprivation-induced apoptosis. As shown in Figure 5a , rhVEGF almost completely blocked the serum deprivation-induced apoptosis. Although the possibility that other factors contribute tumor malignancy through other pathways in solid tumors could not be excluded, VEGF is probably the most eective anti-apoptotic growth factor in tumor cells. Our data also showed the evidence that hypoxia blocked apoptosis with a decreased Bax/Bcl-2 ratio and increased expressions of VEGF and its receptor KDR in serum-deprived HepG2 cells (Figures 3, 5 and 6 ). Furthermore, RTK inhibitors completely blocked antiapoptotic eect of hypoxia ( Figure 6 ). These results strongly suggest that hypoxia-induced VEGF through its receptors activates the MAPK/ERK-related VEGF receptor signaling pathway to elicit anti-apoptotic eects in a self-activating manner. This scenario is con®rmed by the data that rhVEGF inhibits apoptosis of serum-deprived cells with a signi®cant reduction of Bax/Bcl-2 ratio ( Figures 5, 7 and 8) , and anti-VEGF neutralizing antibody completely blocked anti-apoptotic eect of hypoxia ( Figure 5 ). These modulations seem to be adaptive responses of tumors to hypoxic condition prior to initiating new vessel formation.
Further con®rmation was obtained from the treatment of PD98059, which implicates the involvement of the MAPK/ERK signaling pathway in hypoxiainduced anti-apoptosis. PD98059 blocked the antiapoptotic eects of hypoxia or rhVEGF, but did not aect on VEGF expression under hypoxic/serumdeprived condition (Figures 7 and 8) . Thus, our data strongly indicate that hypoxia induces the expression of VEGF prior to the activation of the MAPK/ERK pathway, and that VEGF regulates the expressions of bcl-2 and bax through activation of the signaling pathway. Whether MAPK/ERK pathway directly regulates the expression of bax and bcl-2 is not established but what is clear in the present study is the involvement of the signaling pathway in the regulation of apoptosis of tumor cells.
In the present study, we obtained evidence for the ®rst time showing that a combination of hypoxia with serum deprivation makes tumor cells less-susceptible to apoptosis through MAPK/ERK-dependent VEGF signaling pathway. As schematically presented in Figure 9a serum deprivation-induced Bax activates caspase-3 through cytochrome c release, resulting in apoptosis (Marzo et al., 1998; Finucane et al., 1999) . However, under hypoxic condition, these suppressed Figure 8 Regulation of bax, bcl-2, and VEGF expression through the MAPK/ERK pathway. rhVEGF (100 ng/ml) and PD98059 (50 mM) were treated for 24 h with hypoxia and/or serum deprivation, and (a) RT ± PCR analysis was performed to detect gene expression using speci®c primers for bax, bcl-2, VEGF, and b-actin. (b) Total protein was isolated, and immunoblot analysis was performed using speci®c antibodies. (c) The band intensity was analysed using TINA2.0, and data represents an induction-fold of Bax/Bcl-2 (upper panel) and VEGF expression (lower panel) compared to each control after normalization with a-tubulin band events result in an attenuation of apoptosis of serumdeprived cells through increased VEGF that interacts its receptor KDR as depicted in Figure 9b . According to the scheme, these changes initiate a cascade of events through the MAPK/ERK signaling pathway, resulting in a decrease of Bax/Bcl-2 ratio, cytochrome c release and caspase-3 activation (Figure 9b) . Based on evidence, we concluded that the anti-apoptosis of the combined eect of hypoxia with serum deprivation is mediated by VEGF and the activation of VEGF receptor signaling pathway, which leads to tumor survivability and tumor malignancy.
Materials and methods
Cell culture and hypoxic condition
HepG2 human hepatoblastoma cells (ATCC, Rockville, MD, USA) were maintained in Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum (FBS; GIBCO/BRL, Gaithersburg, MD, USA), 100 units/ml of penicillin and 100 mg/ml of streptomycin (GIBCO/BRL) at 378C in a humidi®ed incubator under 5% CO 2 /95% air. The cells were seeded at a density of 5610 5 cells/60 mm dishes. After 36 h, the cells were washed with serum-free media, replaced with 5 ml of media with or without FBS and incubated under normoxic (5% CO 2 , balanced with air) or hypoxic (1% O 2 , 5% CO 2 , balanced with N 2 ) condition in a humidi®ed incubator (Forma Scienti®c, Inc., Marietta, OH, USA) with an interior temperature of 378C.
DNA isolation and electrophoresis
5610
5 cells/60 mm dish of HepG2 cells were treated with hypoxia and/or serum deprivation for 36 h. The cells were washed twice with ice-cold PBS and lysed with lysis buer (10 mM Tris-HCl, 20 mM EDTA, pH 7.5 and 0.1% Triton X-100) for 30 min at 48C (Baek et al., 1996) . DNA was isolated with phenol-chloroform extraction and treated with RNase (100 ng/ml). DNA was electrophoresed on a 1.5% agarose and photographed under UV light, after staining the gel with ethidium bromide (0.5 mg/ml).
Quantitative analysis of fragmented DNA
HepG2 cells were incubated in growth media for 4 h with 1 mCi/ml [ 3 H]thymidine (Amersham Pharmacia Biotech., UK) (Bhalla et al., 1997) . Then the cells were washed twice with PBS and incubated under hypoxic and/or serum-deprived conditions for 36 h. The cells were washed and lysed with lysis buer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.2% Triton X-100) (Sentman et al., 1991; Baek et al., 1997) . Low and high molecular weight DNA were separated by centrifugation and the amount of 
Morphologic assessment of apoptosis
Nuclear morphology was evaluated using 4,6-diamidino-2-phenylindole (DAPI; Sigma Chemical Co., St. Louis, MO, USA) (Kwo et al., 1995) . Brie¯y, cells were seeded on cover glass and incubated under hypoxic and/or serum-deprived conditions for 36 h. Cells were washed twice with ice-cold PBS, ®xed in 3.7% paraformaldehyde, and then stained with DAPI (5 mM) for 3 min at room temperature. Following rinsing twice with ice-cold PBS, cells were mounted in 60% glycerol and viewed by confocal microscopy (Carl Zeiss, Germany).
Annexin V-FITC Assay
Annexin V, a calcium dependent phospholipid-binding protein with a high anity for phosphatidylserine was used to detect early stage apoptosis (van Engeland et al., 1998; Dhanabal et al., 1999) . After treatment of hypoxia and/or serum deprivation for 12 h, cells were washed with ice-cold PBS and resuspended in binding buer (10 mM HEPES/ NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). The cells were incubated in the dark for 10 min after the treatment of annexin V-FITC (PharMingen, San Diego, CA, USA). Cells were stained with propidium iodide (PI; Sigma Chemical Co.) and subjected to FACScan¯ow cytometry (Becton Dickinson Co., Franklin Lakes, NJ, USA). Data analysis was performed with standard Cell Quest Software (Becton Dickinson Co.). The quadrant settings were set to ascertain the negative control with less than 1% positive signals.
Quantification of cell death
Due to DNA fragmentation, chromatin condensation, and nucleus fragmentation, apoptotic cells have a less DNA content as compared to the G1 cells, which is also called the sub-diploid cells. After treatment of hypoxia and/or serum deprivation for 36 h, cells were harvested, ®xed for at least 30 min in 70% ethanol, and incubated with PI (2.5 mg/ml) and RNase A (50 mg/ml) for 30 min. The number of apoptotic sub-diploid cells was determined using FACScan ow cytometry with Cell Quest Software (Dolbeare and Selden, 1994) . The number of apoptotic cells was expressed as percent of sub-diploid cells (Jinno et al., 1999) . The data of cell cycle distribution were obtained by analysis with ModiFitLT V2.0 (Becton Dickinson, Co.). Figure 9 Hypothetical scheme for the induction of apoptosis by serum deprivation (a) and the inhibition of apoptosis by hypoxia under the serum-deprived condition (b). Serum deprivation increases bax expression and cytochrome c release and activates caspase-3. An increase of Bax/Bcl-2 ratio, cytochrome c release, and caspase-3 activation results in apoptosis. However, hypoxia induces VEGF expression and decreases the ratio of Bax/Bcl-2. Moreover, hypoxia reduces cytochrome c release and caspase-3 activation and consequently inhibits apoptosis. Anti-apoptotic eect of hypoxia-induced VEGF may be mediated through MAPK/ERK signaling pathway
Reverse transcription-PCR (RT ± PCR)
Following treatment of hypoxia and/or serum deprivations for 24 h, total RNA was isolated with TRI Reagent (GIBCO/ BRL). cDNA was synthesized from 5 mg of total RNA with 200 units of MMLV-RT (Promega Co., Madison, WI, USA) and 500 ng of oligo-dT primer. For ampli®cation of cDNAs, oligonucleotide primers and cycle parameters for PCR were designed as shown in Table 1 (Wang and Phang, 1995; Nomura et al., 1995) . PCR products were electrophoresed on agarose gel, and photographed under UV light, after staining with ethidium bromide. The band intensity of PCR product was analysed after normalization with b-actin band using image analysing software of TINA 2.0 (Fuji Inc., Japan).
Preparation of cytosolic extracts and immunoblotting
After exposing to hypoxia and/or serum deprivation for 36 h, the cells were collected and resuspended in 500 ml of extraction buer (50 mM Pipes-KOH, 220 mM mannitol, 68 mM sucrose, pH 7.4, 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol, and protease inhibitors). After 30 min incubation on ice, cells were homogenized using a glass dounce and a tight pestle (50 strokes). Cell homogenates were centrifuged and 10 mg of protein was loaded on 15% SDS-polyacrylamid gels (Finucane et al., 1999) . Mitochondrial cytochrome c was detected with anti-cytochrome c monoclonal antibody (PharMingen).
Caspase-3 assay
After incubation under hypoxic and/or serum-deprived conditions for 36 h, HepG2 cells were harvested, washed twice with ice-cold PBS, and resuspended in lysis buer (10 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 1 mM PMSF, 10 mg/ml pepstatin A, 10 mg/ml aprotinin, 20 mg/ml leupeptin). The rest of the protocol followed the manufacturer's instruction (Bio-Rad Lab., Hercules, CA, USA). The¯uorescence was measured in a microplate reader (BIO-TEK Instruments, Winooski, VT, USA) using 360 nm excitation and 530 nm emission. Data were expressed fold-induction of caspase-3 activity compared to that of control cells.
Northern blot analysis
After treatment with hypoxia and/or serum deprivation, total RNA was isolated and electrophoresed on 1.2% agarose ± 6.6% formaldehyde gels, transfered to Zeta-Probe nylon membrane (Bio-Rad Lab.). Hybridization was then performed with the addition of 20 ng of a-32 P-labeled cDNA probes at 428C for 16 h. a-32 P-labeled DNA probes were prepared by using random prime labeling system (Amersham Pharmacia Biotech.).
Immunoblot analysis
HepG2 cells were treated with hypoxia and/or serum deprivation for 24 h and lysed with lysis buer (40 mM Tris-HCl, pH 7.4, 10 mM EDTA, 120 mM NaCl, 1 mM dithiothreitol, 0.1% Nonidet P-40, and protease inhibitors). Fifty mg of total protein were electrophoresed using 15% SDS-polyacrylamide gels and used for immunoblot analysis using anti-Bax, anti-Bcl-xL, anti-VEGF and anti-KDR polyclonal antibodies and anti-Bcl-2 monoclonal antibody (Santa Cruz Inc., Santa Cruz, CA, USA) (Roy et al., 1997) . For analysis of MAPK/ERK activation, HepG2 cells were treated with rhVEGF (100 ng/ml) for indicated times and immediately lysed with lysis buer (25 mM HEPES, pH 7.6, 0.3 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM DTT, 0.1 mM sodium orthovanadate, 20 mM bglycerophosphate, 4 mM p-nitrophenyl phosphate, 20 mg/ml leupeptin, 1 mM PMSF). Immunoblot analysis was performed using anti-phospho-ERK antibody and anti-ERK antibody that were kindly provided by Dr Rony Seger (Weizmann Institute of Science, Israel). 
